Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: A randomized, placebo-controlled study

Journal of Clinical Oncology

Volumn 29, Issue 20, 2011, Pages 2808-2814

  Le, Quynh Thu ^a   Kim, Harold E ^c   Schneider, Charles J ^d   Muraközy, Györgyi ^e   Skladowski, Krzysztof ^f   Reinisch, Sabine ^g   Chen, Yuhchyau ^h   Hickey, Michael ^b   Mo, May ^b   Chen, Mon Gy ^b   Berger, Dietmar ^b   Lizambri, Richard ^b   Henke, Michael ⁱ  

^a STANFORD UNIVERSITY   (United States)

^b AMGEN INC   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HELEN F GRAHAM CANCER CENTER   (United States)

^e Szent Imre Hospital   (Hungary)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g UNIVERSITY HOSPITAL GRAZ   (Austria)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PALIFERMIN; PLACEBO;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DYSGEUSIA; FEMALE; FLUSHING; HEAD AND NECK CANCER; HUMAN; HYPOKALEMIA; LARYNX PAIN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; ORAL MUCOSAL DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN INJURY; SORE THROAT; TREATMENT RESPONSE; WEIGHT REDUCTION; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; FIBROBLAST GROWTH FACTOR 7; HEAD AND NECK NEOPLASMS; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; STOMATITIS; SURVIVAL ANALYSIS;

EID: 79960257854     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.4095     Document Type: Article

References (30)

1. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data - MACH-NC Collaborative Group - Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000 (Pubitemid 30148259)
2. Cooper JS, Ang KK: Concomitant chemotherapy and radiation therapy certainly improves local control. Int J Radiat Oncol Biol Phys 61:7-9, 2005 (Pubitemid 40039098)
3. Pignon JP, le Maître A, Bourhis J: Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An update. Int J Radiat Oncol Biol Phys 69:S112-S114, 2007 (suppl 2) (Pubitemid 47369400)
4. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003 (Pubitemid 37464533)
5. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004
6. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
7. Peterman A, Cella D, Glandon G, et al: Mucositis in head and neck cancer: Economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 29:45-51, 2001
8. Elting LS, Cooksley CD, Chambers MS, et al: Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68:1110-1120, 2007 (Pubitemid 47048578)
9. Russo G, Haddad R, Posner M, et al: Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist 13:886-898, 2008
10. Vera-Llonch M, Oster G, Hagiwara M, et al: Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106:329-336, 2006 (Pubitemid 43100441)
11. Murphy BA: Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 5:13-21, 2007 (suppl 4)
12. Keefe DM, Schubert MM, Elting LS, et al: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820-831, 2007 (Pubitemid 46335677)
13. Spielberger R, Stiff P, Bensinger W, et al: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590-2598, 2004 (Pubitemid 39628580)
14. Stiff PJ, Emmanouilides C, Bensinger WI, et al: Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 24:5186-5193, 2006 (Pubitemid 46646481)
15. Brizel DM, Murphy BA, Rosenthal DI, et al: Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 26:2489-2469, 2008
16. Zia-Amirhosseini P, Salfi M, Leese P, et al: Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. Clin Pharmacol Ther 79:558-569, 2006 (Pubitemid 43833449)
17. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981 (Pubitemid 11167383)
18. Epstein JB, Beaumont JL, Gwede CK, et al: Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer 109:1914-1922, 2007
19. Landis JR, Heyman ER, Koch GG: Average partial association in three-way contingency tables: A review and discussion of alternative tests. Int Stat Rev 46:237-254, 1978
20. Lehman EL: Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA, Holden Day, 1975
21. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802, 1988
22. Kalbfleisch JD, Prentice RL: The statistical analysis of failure time data. Hoboken, NJ, Wiley, 1980
23. Henke M, Alfonsi M, Foa P, et al: Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: A randomized, placebo-controlled trial. J Clin Oncol 29:2815-2820, 2011
24. Nasilowska-Adamska B, Rzepecki P, Manko J, et al: The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 40:983-988, 2007 (Pubitemid 350048198)
25. Peters LJ, O'Sullivan B, Giralt J, et al: Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results from TROG 02.02. J Clin Oncol 28:2996-3001, 2010
26. Vadhan-Raj S, Trent J, Patel S, et al: Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: A randomized trial. Ann Intern Med 153:358-367, 2010
27. Rischin D, Peters LJ, O'Sullivan B, et al: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28:2989-2995, 2010
28. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007 (Pubitemid 350005151)
29. Brake R, Starnes C, Lu J, et al: Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models. Mol Cancer Res 6:1337-1346, 2008
30. Hille A, Grüger S, Christiansen H, et al: Effect of tumour-cell-derived or recombinant keratinocyte growth factor (KGF) on proliferation and radioresponse of human epithelial tumour cells (HNSCC) and normal keratinocytes in vitro. Radiat Environ Biophys 49:261-270, 2010